Skip navigation
Universidade de Brasília
Use este identificador para citar ou linkar para este item: http://repositorio.unb.br/handle/10482/54454
Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
ARTIGO_CannabidiolComparedPharmacological.pdf1,02 MBAdobe PDFVisualizar/Abrir
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorGallassi, Andrea Donatti-
dc.contributor.authorOliveira, André Wagner Carvalho de-
dc.contributor.authorRodrigues, Larissa Alencar-
dc.contributor.authorNakano, Eduardo Yoshio-
dc.contributor.authorRuas, Pedro A. S.-
dc.contributor.authorLa Mata, José Antonio Iturri de-
dc.contributor.authorFerrari Júnior, Ettore-
dc.contributor.authorGomes, Juliano de Andrade-
dc.contributor.authorCaroba, Mariana Emanuele Silva-
dc.contributor.authorSilva, Marianna Gabriella dos Santos-
dc.contributor.authorVieira, Mariana G. Q.-
dc.contributor.authorReis, Julia G. G. R.-
dc.contributor.authorLeite, Jade Luiza Moreira-
dc.contributor.authorLima, Guilherme Henrique Alves de-
dc.contributor.authorLima, Jonathan Morais-
dc.contributor.authorLima, Yasmim P. V-
dc.contributor.authorRibas, Jorge A. A.-
dc.contributor.authorChagas, Nathalia A. L. das-
dc.contributor.authorMagalhães, Mateus A.-
dc.contributor.authorSilva, Mateus F. da-
dc.contributor.authorFilev, Renato-
dc.contributor.authorLopes, Renato José Rodrigues Malcher-
dc.date.accessioned2026-05-25T11:47:40Z-
dc.date.available2026-05-25T11:47:40Z-
dc.date.issued2024-03-
dc.identifier.citationGALLASSI, Andrea et al. Cannabidiol compared to pharmacological treatment as usual for crack use disorder: a feasibility, preliminary efficacy, parallel, double‑blind, randomized clinical trial. International Journal of Mental Health and Addiction, [S. l.], v. 23, p. 3222–3246, 2025. DOI: https://doi.org/10.1007/s11469-024-01287-z. Disponível em: https://link.springer.com/article/10.1007/s11469-024-01287-z. Acesso em: 13 maio. 2026.pt_BR
dc.identifier.urihttp://repositorio.unb.br/handle/10482/54454-
dc.language.isoengpt_BR
dc.publisherSpringer Naturept_BR
dc.rightsAcesso Abertopt_BR
dc.titleCannabidiol compared to pharmacological treatment as usual for crack use disorder : a feasibility, preliminary efficacy, parallel, double‑blind, randomized clinical trialpt_BR
dc.typeArtigopt_BR
dc.subject.keywordCanabidiolpt_BR
dc.subject.keywordCrack (Droga)pt_BR
dc.subject.keywordDrogas - abuso - psicologiapt_BR
dc.subject.keywordTranstornos relacionados ao uso de substânciaspt_BR
dc.subject.keywordSaúdept_BR
dc.subject.keywordEnsaio clínicopt_BR
dc.rights.licenseOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.pt_BR
dc.identifier.doihttps://doi.org/10.1007/s11469-024-01287-zpt_BR
dc.description.abstract1Cannabidiol (CBD) has been studied for substance use disorders treatment due to its anxiolytic effects, for sleep, appetite, reduction of craving, and maintenance of abstinence. The study aims to assess CBD’s feasibility, safety/tolerability, and preliminary efficacy compared to pharmacological treatment as usual for reducing crack use in people with crack use disorder (CUD) and investigate other parameters: adverse events, physical health symptoms, and craving. A double-blind, randomized clinical trial (RCT) with two treatment arms (CBD and control group) was conducted. Ninety participants were randomized and 73 were allocated: 37 control group and 36 CBD group for a 10-week treatment, comparing CBD (600 mg) with three drugs (fluoxetine, valproic acid, and clonazepam). The per-protocol analysis of participants who did not deviate from the study protocol compared the control and CBD treatment groups. Thirty-four completed at least half of the study and 25 finished. Participants attended weekly meetings for the study procedures (e.g., to receive the medication and provide urine for toxicological tests). Inter-group differences were performed with the Mann–Whitney test, the Wilcoxon test for differences intra-group, and Pearson’s Chi-square test or Fisher’s exact test to compare inter-group demographic data. The significance level was 5%. A “veracity index” (VI) was created as counterevidence (questionnaire data vs. the toxicological test result). Medications were considered safe/tolerable. The CBD group presented significantly fewer adverse events compared to the control group [e.g., dizziness (p = 0.001), memory impairment (p = 0.043)], which performed better in the reduction of clinical and psychiatric complaints (p = 0.008). In the intra-group analyses, the CBD group performed better in more parameters than the control group [e.g., reducing crack use (p = 0.016; T0 to T1)]. Data questionnaires were reliable regarding the use/non-use of crack (VI = 0.787). CBD is a safe/tolerable product. The CBD group manifested fewer adverse events than the control group, which had better clinical and psychiatric complaints results. There are some advantages for the CBD group in the intra-group analysis. Drug use self-report methodologies can be reliable. Trial registration details: This study is registered with Universal Trial Number (UTN) code: U1111-1234- 0806.pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0003-1852-485Xpt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-8041-2133pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-6469-4318pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-9071-8512pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-1310-2634pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-6598-1861pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-2953-7878pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-5990-765Xpt_BR
dc.identifier.orcidhttps://orcid.org/0000-0003-1194-1407pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-1484-3856pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-8274-7882pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-1129-2163pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0003-2487-0118pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-8571-1351pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-0273-0635pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-9782-9258pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-4363-2011pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-4980-6799pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-7628-9267pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-9238-0455pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-4941-9908pt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Graduate Program in Health Sciences and Technologypt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Center of Drugs and Associated Vulnerabilitiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Graduate Program in Health Sciences and Technologypt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Center of Drugs and Associated Vulnerabilitiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Graduate Program in Health Sciences and Technologypt_BR
dc.contributor.affiliationSecretary of Health of the Brazilian Federal Districtpt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Undergraduate Program in Public Healthpt_BR
dc.contributor.affiliationCivil Police of the Brazilian Federal District, Forensic Institutept_BR
dc.contributor.affiliationCivil Police of the Brazilian Federal District, Forensic Institutept_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Center of Drugs and Associated Vulnerabilitiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Undergraduate Program in Occupational Therapypt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Center of Drugs and Associated Vulnerabilitiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Undergraduate Program in Occupational Therapypt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Center of Drugs and Associated Vulnerabilitiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Undergraduate Program in Occupational Therapypt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Center of Drugs and Associated Vulnerabilitiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Undergraduate Program in Occupational Therapypt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Center of Drugs and Associated Vulnerabilitiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Undergraduate Program in Pharmacypt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Center of Drugs and Associated Vulnerabilitiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Undergraduate Program in Pharmacypt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Center of Drugs and Associated Vulnerabilitiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Undergraduate Program in Pharmacypt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Center of Drugs and Associated Vulnerabilitiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Undergraduate Program in Pharmacypt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Center of Drugs and Associated Vulnerabilitiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Undergraduate Program in Pharmacypt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Center of Drugs and Associated Vulnerabilitiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Undergraduate Program in Pharmacypt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Center of Drugs and Associated Vulnerabilitiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ceilândia, Undergraduate Program in Pharmacypt_BR
dc.contributor.affiliationUniversidade de Brasília, Campus Darcy Ribeiro, Institute of Psychologypt_BR
dc.contributor.affiliationUniversidade Federal de São Paulo, Orientation and Assistance Program for Dependentspt_BR
dc.contributor.affiliationUniversidade de Brasília, Campus Darcy Ribeiro, Institute of Biologypt_BR
dc.description.unidadeFaculdade de Ciências e Tecnologias em Saúde (FCTS) – Campus UnB Ceilândiapt_BR
dc.description.unidadeCurso de Terapia Ocupacional (FCTS-TER)pt_BR
dc.description.unidadeFaculdade de Ciências da Saúde (FS)pt_BR
dc.description.unidadeDepartamento de Farmácia (FS FAR)pt_BR
dc.description.unidadeDepartamento de Saúde Coletiva (FS DSC)pt_BR
dc.description.unidadeInstituto de Ciências Exatas (IE)pt_BR
dc.description.unidadeDepartamento de Estatística (IE EST)pt_BR
dc.description.unidadeInstituto de Psicologia (IP)pt_BR
dc.description.unidadeInstituto de Ciências Biológicas (IB)pt_BR
dc.description.unidadeDepartamento de Ciências Fisiológicas (IB CFS)pt_BR
dc.description.ppgPrograma de Pós-Graduação em Ciências e Tecnologias em Saúdept_BR
Aparece nas coleções:Artigos publicados em periódicos e afins

Mostrar registro simples do item Visualizar estatísticas



Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.